Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Lymphoma 35Small Cell Lung Carcinoma 34Leukemia 34Lung Neoplasms 25Leukemia, Myeloid, Acute 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, Large B-Cell, Diffuse 19Neuroblastoma 15Lymphoma, Non-Hodgkin 15Carcinoma, Non-Small-Cell Lung 14Leukemia, Erythroblastic, Acute 13Hodgkin Disease 13Leukemia, Myelomonocytic, Acute 12Leukemia, Monocytic, Acute 12Leukemia, Megakaryoblastic, Acute 12Sarcoma 11Lymphoma, Follicular 10Burkitt Lymphoma 10Lymphoma, Large-Cell, Immunoblastic 9Testicular Neoplasms 7Teratoma 7Myelodysplastic Syndromes 7Congenital Abnormalities 7Multiple Myeloma 6Endodermal Sinus Tumor 6Anemia, Refractory, with Excess of Blasts 6Testicular Germ Cell Tumor 5Ovarian Neoplasms 5Neuroectodermal Tumors, Primitive, Peripheral 5Central Nervous System Neoplasms 5

Interventions

Radiotherapy 2Paclitaxel 2Fluorouracil 2Etoposide 2Carboplatin 2etoposide phosphate 1Vincristine 1Porfiromycin 1Mitomycin 1Leucovorin 1Irinotecan 1Gemcitabine 1Epirubicin 1Doxorubicin 1Dexamethasone 1Cyclophosphamide 1Cisplatin 1Brachytherapy 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms, Unknown Primary × Etoposide × Clear all
NCT00003558 2013-08-07

Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin

National Cancer Institute (NCI)

Phase 3 Unknown
140 enrolled
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00193596 2013-05-03

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 3 Completed
198 enrolled 7 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡